Agenus calls out FDA for play­ing fa­vorites with Mer­ck, pulls cer­vi­cal can­cer BLA at agen­cy's re­quest

While crit­i­ciz­ing the FDA for what may be some fa­voritism to­wards Mer­ck, Agenus on Fri­day of­fi­cial­ly pulled its ac­cel­er­at­ed BLA for its an­ti-PD-1 in­hibitor bal­stil­imab …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.